EICHOR
● Completed
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
Condition: HIV-1 Infection · Sponsor: Merck Sharp & Dohme LLC
About this study
This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0.75 mg islatravir (DOR/ISL \[also known as MK-8591A\]) in treatment-naïve participants living with human immunodeficiency virus type-1 (HIV-1) infection. The primary objectives are to evaluate the antiretroviral activity, safety, and tolerability of DOR/ISL compared to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that DOR/ISL is noninferior or superior to BIC/FTC/TAF treatment based on the percentage of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (95)
| University of Alabama at Birmingham 1917 Research Clinic ( Site 5610) | Birmingham, Alabama, United States | — |
| Pueblo Family Physicians ( Site 5606) | Phoenix, Arizona, United States | — |
| Ruane Clinical Research Group, Inc. ( Site 5624) | Los Angeles, California, United States | — |
| Midway Immunology and Research ( Site 5622) | Ft. Pierce, Florida, United States | — |
| The Kinder Medical Group ( Site 5615) | Miami, Florida, United States | — |
| Floridian Clinical Research, LLC ( Site 5625) | Miami Lakes, Florida, United States | — |
| Orlando Immunology Center ( Site 5613) | Orlando, Florida, United States | — |
| CAN Community Health ( Site 5627) | Sarasota, Florida, United States | — |
| Triple O Research Institute, P.A. ( Site 5621) | West Palm Beach, Florida, United States | — |
| Columbus Regional Research Institute ( Site 5616) | Columbus, Georgia, United States | — |
| Infectious Disease Specialists Of Atlanta PC ( Site 5608) | Decatur, Georgia, United States | — |
| Hennepin Healthcare-Hennepin Healthcare-ID ( Site 5633) | Minneapolis, Minnesota, United States | — |
+ 83 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04233879